FindTrial
Sign In

Evaluation of biomarker levels in patients with periodontitis

Evaluation of Soluble Neuropilin-1 levels in patients with Periodontitis: A case control study - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/03/063800
Enrollment
48
Registered
2024-03-07
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K053- Chronic periodontitis

Interventions

Intervention1: Scaling and root planing: Saliva samples for estimation of soluble neuropilin-1 will be collected at baseline and 3 months. Control Intervention1: Scaling (if required): Saliva samples

Sponsors

Dr. Luchun Tanya Pamei
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: INCLUSION CRITERIA Group A – 1.Patients aged between 20-40 years 2.Patients with stage I - II periodontitis with interdental clinical attachment loss of 1-4mm with probing pocket depth =4-5mm in atleast 6 teeth. 3. Bleeding on probing >10%. 4. Patients who had not undergone periodontal treatment in past 3 months. 5. Patients willing to participate in the study. Group B – 1.Periodontally healthy individuals with no clinical attachment loss and radiographic bone loss. 2.Patients aged between 20-40 years. 3. Bleeding on probing 4.Patients who did not receive treatment in past 3 months. 5. Patients willing to participate in the study.

Exclusion criteria

Exclusion criteria: EXCLUSION CRITERIA 1. Patients suffering from any metabolic diseases. 2. Lactating and pregnant females. 3. Patients with history of antibiotics in past 3 months and currently on pain killers 4. Patients with wasting diseases where cemento-enamel junction is not visible. 5. History of patients with salivary gland diseases.

Design outcomes

Primary

MeasureTime frame
1.To evaluate salivary soluble neuropilin-1 levels using ELISA and clinical parameters in patients with stage I-II periodontitis at baseline and 3 months. 2.To evaluate salivary soluble neuropilin-1 levels and clinical parameters using ELISA with periodontally healthy patients at baseline and 3 months. Timepoint: Baseline, 1 month and 3 months—

Secondary

MeasureTime frame
To compare and evaluate salivary soluble neuropilin-1 levels using ELISA and clinical parameters in patients with stage I-II periodontitis and periodontally healthy patients at baseline and 3 months.Timepoint: Baseline, 1 month and 3 months—

Countries

India

Contacts

Public ContactLuchun Tanya Pamei

Manav Rachna Dental College

ruchi.sds@mrei.ac.in7799690877

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026